There was plenty to like in Amazon's earnings report. Figuring out how they correspond to some analysts' actual nomenclature can be quite a challenge. Trying to understand the distinctions in ratings can make an investor crazy. Which is one of the reasons Fools try to rely primarily on themselves to understand earnings information. Especially considering that given any particular set of facts, any two people can make a successful bullish or bearish argument.
Fools know that it's impossible to time the market.
Making short-term calls may help you reduce some losses occasionally, but it may also keep you out of the stock when there's positive news that may make the stock soar. We Rule Breaking Fools will dust off our comfy cushion and begin to enjoy the ride as we HOLD onto our shares. While there had been some journalists who questioned Celera's valuation and wondered how the company would ever generate profits, no one came straight out and attacked the stock. A front page article in the Business Section of The Wall Street Journal mentions that Stuart Weisbrod, portfolio manager for the Merlin BioMed Group, is short-selling Celera because as hard as he tries, he can't figure out how the company is going to make money. For Foolish speculation and potential thoughts on CRA's ability to transform its discoveries into profits, review our CRA Buy Report .